This is part 3 of a series on How to successfully implement AI. Part 1 covered what AI is. Part 2 covered how Condor uses AI to produce numbers you can trust. This one covers why generic AI can’t do clinical trial finance.
Finance teams across biopharma are connecting ChatGPT and Claude to their clinical trial data and asking for accruals, variance explanations, and spend forecasts. Generic AI is excellent at conversational finance work: synthesizing documents, drafting memos, ad hoc analysis, and finance teams should be using it today.
But as many companies are finding out, building an AI interface is easy. The hard part is the underlying context engineering, validation, domain expertise, and operational understanding required to make outputs trustworthy and actionable.
Clinical trial finance is a reasoning problem over a structured system of record, and generic AI lacks the architecture required to reason reliably over that system.
That’s because generic AI wasn’t purpose-built for the complexity of clinical trial finance. As a result, it often produces inconsistent results on subjective estimates (aka clinical accruals). Here are the three reasons why generic AI isn't precise enough for clinical trial finance, and what the right architecture looks like.
As finance leaders, we know a simple truth: before you can understand the finances, you must understand the business. Generic AI is no different.
Every number depends on protocols, patient enrollment, site activity, vendor contracts, change orders, milestones, pass-through costs, and accounting policies. To understand the financial outcome, you first need to understand the operational reality driving it.
Generic AI reasons over text. It does not understand how your trial operates, or have the necessary domain context. Clinical trial finance is a relational problem — a web of interdependent contracts, protocol events, accounting rules, and cost structures that must all align before a number is trustworthy.
You can add specific business and clinical context to help your analysis. But as you read below, you’ll see that’s not enough. This is why standard accounting reconciliation processes are good candidates for generic AI, but they can be dangerous when used for a deeply specialized and industry-specific workflow.
For example, if you ask it what "pass-through costs" are, it will know the dictionary definition, and it might be able to make a guess on how it applies. It doesn’t know the nuances within the pass-through costs, why they’ve been contracted, what it means to the clinical trial itself, and what operational drivers affect those costs.
Generic AI will also understand clinical accruals or forecasting very broadly. But you’ll have to spend a lot of time engineering the context to understand what happens on a given protocol, what the assessments are, why they matter, the logic behind visits in the EDC, what the CROs are contractually doing, what the different imaging vendors are doing, and the inflection points you're executing against.
Let’s say you initially engineer this context and map it to your business. Your model will still drift without grounding.
After the context, the next hurdle is grounding and drift.
A hallucination is when generic AI generates information that is factually incorrect, fabricated, or nonsensical, but presents it with apparent confidence, as if it were true. For example, the analysis tells you “The CRO amendment increased costs by $2.3M”, but no amendment exists. Hallucinations aren’t a bug that gets fixed. They’re a structural property of how generic AI works. It has no mechanism to check whether what it's saying is true. And that's a gap.
Drift is another problem. It’s gradual degradation or shift in an AI model's performance, behavior, or outputs over time. The answer can sound perfectly reasonable, use real information, and still solve the wrong problem. For example, the analysis started answering your question, "How much cash do we need to reach the last patient dosed?", and 10 steps later it’s optimizing the study timeline rather than answering the cash requirement question. The numbers may be real. The model is just solving the wrong problem.
Both failures stem from the same issue: the model has no source of truth. Grounding is what closes this gap.
Your enrollment and site administration lives in clinical systems, contracts in executed agreements live in multiple systems, your budget and forecast may live in different systems or on a spreadsheet — none sharing a data model. They need to share a data model and know how to relate with one another in order to be precise and effective. This is what enables the lineage (or audit trail described below).
A grounded system ties every claim to a structured source of truth: an ontology defining what entities exist, a knowledge graph defining how they relate, and deterministic rules the output must satisfy before providing probabilistic results.
Generic AI has none of this. Working from a flat export, the model has no way to know what it doesn't know. The result is confident, specific, and unverifiable (or unauditable). In a regulated industry that needs reliability, consistency and accuracy, that’s a very dangerous kind of wrong.
Here's the ultimate test: ask any AI system to show its work; not just the answer. Show the exact contracts, enrollment data, site activity, assumptions, accounting policies, and calculations that produced the number. Show how they relate to one another. Show what changed since last month. Show what drove the variance.
Generic AI can't do this.
Even when it produces the correct answer, it cannot reliably explain the chain of reasoning that led there. Its outputs are generated through statistical inference, not a documented chain of evidence. There is no persistent record connecting the underlying clinical and financial data to the final result.
This becomes a major problem in clinical trial finance because trust isn't created by the number itself. Trust comes from understanding how the number was produced.
Every accrual, forecast, and scenario depends on hundreds of interconnected assumptions across protocols, contracts, enrollment, site activity, vendor spend, accounting policy, and financial controls. If you cannot trace the output back through those relationships, you cannot validate it, defend it, or audit it.
This is where lineage becomes essential.
Lineage creates a complete chain of custody from source data to financial outcome. It shows which systems were used, how the data was mapped, which business rules were applied, what assumptions were made, and how every calculation was derived. When an executive asks a question, the answer isn't simply generated — it is supported.
In regulated industries, explainability isn't optional. Auditors require it, controllers depend on it, and regulators expect it. And finance leaders need it before they can trust AI with material decisions.
Without lineage, AI produces answers. With lineage, AI produces evidence.
Condor was built to solve exactly these three problems.
Domain context is built in. Condor was designed specifically for clinical trial finance, with years of clinical and financial knowledge embedded into its foundation. Condor's platform is built on proprietary clinical and financial ontologies that understand the relationships between protocols, enrollment, site activity, vendor contracts, budgets, forecasts, and accounting rules because those relationships are native to the system; not added later through prompts or manual configuration. These ontologies were developed over years with Big 4 accounting firms; not configured after the fact, but architected into the foundation. When Condor calculates an accrual, it is applying rules that reflect how clinical trial finance actually works.
Grounding mitigates hallucination and drift. The knowledge graph in Condor continuously connects your live clinical, operational and financial data across the systems biopharma companies already use — CTMS, EDC, IVRS, CRO contracts — to a structured model of how that data relates to financial obligations. There is no gap-filling. When enrollment changes, sites activate, milestones are achieved, or change orders are approved, the financial impact is reflected automatically. The platform isn't inferring what happened. It understands what happened and how it affects the forecast, accrual, and budget. The AI reasons against a ground truth it can prove.
Every number is explainable and comes with an audit trail. Finance teams can trace results back to the underlying contracts, operational activities, assumptions, and accounting rules that produced them. The platform doesn't just provide an answer; it provides the evidence behind the answer.
The difference between generic AI and a purpose-built clinical financial intelligence platform isn't a feature gap. It's an architecture gap. One was designed to generate plausible answers. The other was designed to produce numbers you can prove and explain.
In clinical trial finance, that distinction matters. It determines whether forecasts are credible, whether accruals are defensible, whether auditors can validate the process, and ultimately whether management teams have the confidence to make the right business decisions.
The good news is that these technologies are complementary. Generic AI is excellent for research, analysis, and productivity. Purpose-built clinical financial intelligence platforms provide the trusted data and operational foundation those tools need to be effective so they can operate with confidence and bring therapies to patients faster and more cost effectively.
Condor can help you elevate your R&D finance function into an AI-native one by enriching your generic AI with domain context, grounding it to prevent hallucinations and drift, and creating an audit trail. Schedule some time with our experts to learn more.
Condor is the Financial Intelligence Platform for life sciences R&D. Learn more at condorsoftware.com.
